DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of a fixed brimonidine-timolol combination on intraocular pressure after phacoemulsification.

Author(s): Pharmakakis N, Giannopoulos K, Stasinos S, Makri OE, Georgakopoulos CD

Affiliation(s): Department of Ophthalmology, University of Patras, Medical School, Patras, Greece.

Publication date & source: 2011-02, J Cataract Refract Surg., 37(2):279-83.

Publication type: Randomized Controlled Trial

PURPOSE: To evaluate the effect of a fixed combination of brimonidine-timolol on intraocular pressure (IOP) after phacoemulsification cataract surgery. SETTING: Department of Ophthalmology, Patras University Hospital, Patras, Greece. DESIGN: Prospective randomized comparative case series. METHODS: Patients scheduled for phacoemulsification were randomly assigned to 1 of 2 groups. The treatment group received 1 drop of brimonidine-timolol fixed combination immediately after surgery, and the control group received no treatment. The IOP was measured preoperatively and 6, 12, and 24 hours postoperatively. RESULTS: The treatment group comprised 28 eyes and the control group, 30 eyes. The mean IOP increased by 0.14 mm Hg +/- 3.88 (SD) (P = .88) in the treatment group and increased by 2.8 +/- 5.01 mm Hg (P = .007) in the control group. Twelve hours after surgery, the mean IOP decreased by -0.57 +/- 3.82 mm Hg (P = .49) in the treatment group and increased by 2.20 +/- 4.56 mm Hg (P = .009) in the control group. Twenty-four hours after surgery, the mean IOP decreased by -1.57 +/- 2.30 mm Hg (P=.012) in the treatment group and increased by 0.86 +/- 4.21 mm Hg (P = .175) in the control group. The mean IOP change between the 2 study groups 6, 12, and 24 hours postoperatively was statistically significantly different (P = .015, P = .006, and P = .003; respectively). CONCLUSION: The fixed brimonidine-timolol combination effectively reduced IOP 6, 12, and 24 hours after phacoemulsification cataract surgery. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012